High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas.
- 21 November 1995
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 92 (24) , 10854-10858
- https://doi.org/10.1073/pnas.92.24.10854
Abstract
Malignant mesotheliomas (MMs) are aggressive tumors that develop most frequently in the pleura of patients exposed to asbestos. In contrast to many other cancers, relatively few molecular alterations have been described in MMs. The most frequent numerical cytogenetic abnormality in MMs is loss of chromosome 22. The neurofibromatosis type 2 gene (NF2) is a tumor suppressor gene assigned to chromosome 22q which plays an important role in the development of familial and spontaneous tumors of neuroectodermal origin. Although MMs have a different histogenic derivation, the frequent abnormalities of chromosome 22 warranted an investigation of the NF2 gene in these tumors. Both cDNAs from 15 MM cell lines and genomic DNAs from 7 matched primary tumors were analyzed for mutations within the NF2 coding region. NF2 mutations predicting either interstitial in-frame deletions or truncation of the NF2-encoded protein (merlin) were detected in eight cell lines (53%), six of which were confirmed in primary tumor DNAs. In two samples that showed NF2 gene transcript alterations, no genomic DNA mutations were detected, suggesting that aberrant splicing may constitute an additional mechanism for merlin inactivation. These findings implicate NF2 in the oncogenesis of primary MMs and provide evidence that this gene can be involved in the development of tumors other than nervous system neoplasms characteristic of the NF2 disorder. In addition, unlike NF2-related tumors, MM derives from the mesoderm; malignancies of this origin have not previously been associated with frequent alterations of the NF2 gene.Keywords
This publication has 35 references indexed in Scilit:
- Rates of p16 ( MTS1 ) Mutations in Primary Tumors with 9p LossScience, 1994
- The neurofibromatosis 2 (NF2) tumor suppressor gene encodes multiple alternatively spliced transcriptsHuman Molecular Genetics, 1994
- WT1 -Mediated Growth Suppression of Wilms Tumor Cells Expressing a WT1 Splicing VariantScience, 1993
- DNA diagnosis of neurofibromatosis 2. Altered coding sequence of the merlin tumor suppressor in an extended pedigreePublished by American Medical Association (AMA) ,1993
- The Wilms tumour gene WT1 is expressed in murine mesoderm–derived tissues and mutated in a human mesotheliomaNature Genetics, 1993
- ALTERNATIVE SPLICING IN THE CONTROL OF GENE EXPRESSIONAnnual Review of Genetics, 1989
- Neurofibromatosis 2New England Journal of Medicine, 1988
- Genetic linkage of bilateral acoustic neurofibromatosis to a DNA marker on chromosome 22Nature, 1987
- Common Pathogenetic Mechanism for Three Tumor Types in Bilateral Acoustic NeurofibromatosisScience, 1987
- Loss of genes on chromosome 22 in tumorigenesis of human acoustic neuromaNature, 1986